Analysis of drug incompatibilities in a cardiac intensive unit: a cross-sectional study
Abstract
Objective: To evaluate the incompatibilities of intravenous medications in cardiac patients admitted to a cardiac intensive unit, associating possible incompatibilities with the severity and characteristics of the adverse event.
Method: Cross-sectional, observational, and quantitative study, held in a Cardiac intensive Unit of a University Hospital in the city of Rio de Janeiro. Data collection took place from March to June 2018. Micromedex® identified and classified drug incompatibilities.
Results: We analyzed 111 prescriptions with a total of 1,497 prescription drugs, the average number of prescription drugs was 13.49 (6 ± 24), 580 (38.74%) intravenously in which 41.38% were administered simultaneously with another medicine. The study showed 121 incompatibilities and the drug classes that had the highest number of incompatibilities were diuretics, hypnotics and sedatives, cardiovascular stimulants (vasoactive amines), antibiotics for systemic use, corticosteroids for systemic use, cardiovascular vasodilators, and antiarrhythmic agents. We highlight the incompatibilities classified as moderate, furosemide with hydrocortisone, and midazolam with omeprazole, and severe fentanyl with amiodarone.
Conclusion: The study highlights the importance of medication scheduling and administration by the nursing team based on pharmacological knowledge. We expect that the chart of recommendations prepared in the study with nursing care related to incompatibilities with greater potential for severity and its events can contribute to drug safety.
Downloads
References
Marsilio N, Silva D, Bueno D. Incompatibilidades medicamentosas em centro de tratamento intensivo adulto de um hospital universitário. Rev Bras Ter Intensiva. Porto Alegre. 2016; 28(2)147-153. DOI: http://dx.doi.org/10.5935/0103-507X.20160029
Cerdá S, Palau M, Nicolau R, Rubert M, Juan E. Administración compatible de la terapia intravenosa continua em el paciente coronário crítico. Enferm Cardiol. España, 2013; 59(2): 46-49.
Leal K, Leopoldino R, Verissimo L. Potencial de incompatibilidade de medicamentos intravenosos em uma unidade pediátrica. Einstein. Natal, 2016;14(2):185-9. DOI: https://doi.org/10.1590/S1679-45082016AO3723
World Health Organization. Medication Without Harm - Global Patient Safety Challenge on Medication Safety. Geneva: World Health Organization; 2017. [acess 2020 jul 06]. Available from: https://www.who.int/patientsafety/medication-safety/medication-without-harm-brochure/en/
Prelhacoski D, Silva D, Comarella L. Incompatibilidade medicamentosa em Unidade de Terapia Intensiva Pediatrica. UNIANDRADE. Paraná, 2016; 16(2):73-81. DOI: http://dx.doi.org/10.18024/1519-5694/revuniandrade.v16n2p73-81
Paixão, FM, Camerini, FG, Fassarella, CS, Henrique, DM, Assad, LG, Radighieri, AR. Gravidade das incompatibilidades medicamentosas em pacientes críticos: Uma revisão integrativa. Saúde Coletiva (Barueri), 2019; 9(51):1907-1912.DOI: https://doi.org/10.36489/saudecoletiva.2019v9i51p1907-1912
Malconi M, Lakatos E. Fundamentos de metodologia científica. 7. Ed-São Paulo: Atlas, 2010.
Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMFP. Iniciativa STROBE: subsídios para a comunicação de estudos observacionais. Rev. Saúde Pública. 2010;44( 3 ): 559-565. DOI: https://doi.org/10.1590/S0034-89102010000300021
Micromedex® 2.0. Truven Health Analytics Inc. 2013. [acesso em 10 out 2019]. Available from: http://www.micromedexsolutions.com .
World Health Organization (WHO). WHO Collaborating Centre on Drug Statistics Methodology. ACT/DDD Index 2019 [Internet]. Oslo, Noruega: WHO; 2019. [cited 2020 Apr 26]. Available from: http://www.whocc.no/atc_ddd_index/
Ondrej M, Jan M, Ales K, Jiri V. Incidence of intravenous drug incompatibilities in intensive care units. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015; 159(4):652-656. DOI: https://doi.org/10.5507/bp.2014.057
Benlabed M, Perez M, Gaudy R, et al. Clinical implications of intravenous drug incompatibilities in critically ill patients. Anaesth Crit Care Pain Med. 2019;38(2):173-180. DOI: https://doi.org/10.1016/j.accpm.2018.04.003
Santos L, Martinbiancho J, Tadiotto A, Kreutz L. Perfil das interações medicamentosas solicitadas ao Centro de Informações sobre Medicamentos de hospital universitário. Clinical and Biomedical Research [Internet]. 2011 [acesso em 27 jul 2020];31(3):326-35. Avaible from: http://seer.ufrgs.br/hcpa/article/view/22183 .
Paes GO, Moreira SO, Moreira MB, Martins TG. Incompatibilidade medicamentosa em terapia intensiva: revisão sobre as implicações para a prática de enfermagem. Rev. Eletr. Enf. 2017; 19. DOI: http://dx.doi.org/10.5216/ree.v19.38718 .
Cortes ALB, Silvino ZR. Fatores associados a interações medicamentosas potenciais em um Centro de Terapia Intensiva: estudo transversal. Esc. Anna Nery . 2019; 23( 3 ): e20180326. DOI: http://dx.doi.org/10.1590/2177-9465-ean-2018-0326 .
Scrignoli CP, Teixeira VCMC, Leal DCP. Drug interactions among the most prescribed drugs in adult intensive care unit. Rev Bras Farm Hosp Serv Saude [Internet]. 2019. [citado em 2 de abril de 2020];7(2). Avaible from: https://rbfhss.org.br/sbrafh/article/view/252 .
Agência Nacional de Vigilância Sanitária (Brasil). Bulário eletrônico da Anvisa. [acesso em 20 out 2018]. Avaible from: http://www.anvisa.gov.br/bularioeletronico/
Santos MDP et al. Conhecimento de profissionais de enfermagem de um hospital público sobre interações medicamentosas. Uningá Review. 2016; .28 (1):39-44. [acesso em 20 out 2018]. Avaible from: http://revista.uninga.br/index.php/uningareviews/article/view/1848/1448
Bertsche T, Veith C, Stahl A, Hoppe-Tichy T, Meyer FJ, Katus H, et al. A purging procedure for pantoprazole and 4lumen catheters to prevent IV drug incompatibilities. Pharm World Sci. 2010; 32:663–669. DOI: http://dx.doi.org/10.1007/s11096-010-9422-9 .
Negeliskii C. Efeito de uma intervenção educativa com profissionais de enfermagem acerca da segurança do paciente na administração de medicamentos injetáveis. [acesso em 20 out 2019]. Avaible from: Porto Alegre, 2015. https://proqualis.net/sites/proqualis.net/files/000978150.pdf
The works published in this magazine are subject to the following terms:
1. The Publications Service of the University of Murcia (the publisher) preserves the copyright of the published works, and encourages and allows the reuse of the works under the license for use stated in point 2.
© Servicio de Publicaciones, Universidad de Murcia, 2011 (© Publications Service, University of Murcia, 2011)
2. The works are published in the electronic edition of the journal under Creative Commons Reconocimiento-NoComercial-SinObraDerivada 3.0 España(texto legal) “ a Attribution-NonCommercial-NoDerivatives 3.0 Spain license (legal text)”. They can be copied, used, broadcasted, transmitted and publicly displayed, provided that: i) the authorship and original source of their publication (journal, publisher and URL) are cited; (ii) are not used for commercial purposes; iii) the existence and specifications of this license is mentioned.
3. Conditions of self-archiving. Authors are allowed and encouraged to electronically disseminate the pre-print (pre-reviewed ) and / or post-print (reviewed and accepted for publication) versions of their works prior to publication, as it ensures a wider circulation and dissemination which may lead to a possible increase in its mention and a higher scope among the academic community. RoMEO color: green.
